-
September 28, 2018
Annual Report 2018 -
July 31, 2018
R&D Pipeline as of July 2018 -
July 31, 2018
The First Quarter of FY2018 (April 2018 - June 2018) -
May 8, 2018
Annual of FY2017 (April 2017 - March 2018) -
January 31, 2018
The Third Quarter of FY2017 (April 2017- December 2017)
-
September 21, 2018
Kyorin Receives Marketing Approval in Japan for "Beova® Tablets 50mg" for the Treatment of Overactive Bladder -
May 30, 2018
Kissei Announces Negative Topline Results from the additional phase III Clinical Trial evaluating "KPS-0373 (Development Code)" for the Treatment of Spinocerebellar Ataxia -
April 23, 2018
Kissei Announces New President and COO -
January 17, 2018
JR-131, a Long-Acting Erythropoiesis-Stimulating Agent, Demonstrates Equivalence in Phase III Study -
December 6, 2017
Ulcerative Colitis Treatment "RECTABUL® 2 mg Rectal Foam 14 Doses" Launches in Japan
